Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) said it has entered into a research collaboration agreement with PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, to evaluate the delivery of psilocybin with PharmaTher’s proprietary microneedle (MN) patch technology for neuropsychiatric disorders.
Revive said PharmaTher is currently conducting Investigational New Drug-enabling research studies with MicroDose-MN, a patent-pending biocompatible and biodegradable gelatin methacryloyl microneedle patch, to deliver psilocybin to support an investigational new drug application with the US Food and Drug Administration for clinical studies in 2022.
Research results with MicroDose-MN for psilocybin will be made available in November by PharmaTher.
READ: Revive Therapeutics says DSMB supports continuation of its Phase 3 trial of Bucilllamine for mild COVID-19
Revive said it is building a specialty psilocybin-based product pipeline, aiming to treat mental illness, substance abuse, and neurological disorders.
In addition to the proposed psilocybin MicroDose-MN patch, the company has the following development and commercial programs:
- Feasibility agreement with LTS Lohmann Therapie-Systeme AG, a leader in pharmaceutical oral thin films, to develop and manufacture a proprietary psilocybin oral thin-film strip;
- Evaluating psilocybin as a potential treatment for methamphetamine use disorder, traumatic brain injury, and stroke in a research collaboration with the University of Wisconsin-Madison;
- Developing a novel biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform under its research collaboration with North Carolina State University; and
- Research and commercialization agreement with the University of Health Sciences Antigua to utilize Revive’s novel psychedelic-assisted therapies including its tannin-chitosan delivery system and to pioneer the clinical research and development of psychedelics in Antigua and Barbuda and commercial partnerships with specialty pharmaceutical companies in the Caribbean and Latin America.
Revive said the collaboration agreement will give it the ability to evaluate the MicroDose-MN for psilocybin program to support upcoming clinical and commercial developments globally.
"We are maintaining our focus in building a unique psilocybin-based product portfolio through research collaborations, licensing and commercialization agreements with academic research institutions and specialty pharmaceutical companies,” said Revive CEO Michael Frank.
“The collaboration with PharmaTher complements our psilocybin product offerings as potential treatments for mental illness, substance abuse and neurological disorders. We believe there is no one fits all product profile solution with psilocybin and that for psilocybin to be a next generation therapeutic, it will require different use and delivery forms to achieve the intended target indications. As such, we aim to become a leader in psilocybin-based solutions for unmet medical needs by collaborating with companies that have intellectual property and experience in their delivery technologies.”
Fabio Chianelli, CEO of PharmaTher, noted that its proprietary microneedle patch can deliver various psychedelics via the skin, enable flexible drug load capacity and combinations, and control-release delivery, and overcome the potential drawbacks of oral administration.
He added that the technology can “empower patients to dose their medication remotely, safely and conveniently rather than under supervision by a healthcare provider at a certified medical office.”
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham